Note from the editor: Small but important changes ahead

By Jenni Spinner

- Last updated on GMT

(We Are/iStock via Getty Images Plus)
(We Are/iStock via Getty Images Plus)

Related tags Decentralized trials Clinical trials Clinical trial Patient centricity Contract research organization Clinical research Drug development Pharmaceutical industry

The past two years have been full of shifts and shakes in the drug development field, but the change at Outsourcing-Pharma is easy and one for the better.

Flexibility is a necessary survival skill in this day and age. If someone can’t adapt to keep up with the times, they will let their customers down and risk falling behind.

Sometimes, the changes required to keep pace are difficult—a good example appropriate to Outsourcing-Pharma might be changing course from on-site studies to decentralized trials. In other instances, adaptation is less of a struggle yet still worth making (switching your daily cola at lunch to a diet to save on calories).

The change we’re making at Outsourcing-Pharma definitely falls into the latter camp. True, it’s an adjustment for both us and our readers; however, it’s a fairly easy transition that will lead to a range of worthwhile benefits across the board.

Readers like you are more engaged with our publication than ever before. In 2019, our content had about 767,000 views in a year; just two years later, in 2021, that same number was about 1.2m. That shows us we’re headed in the right direction, in terms of delivering the industry coverage you and your colleagues are interested in.

The next step in ensuring we deliver the best drug-development content possible is deepening the connection with readers like you. We will be asking our audience to register and provide a few professional details. It’s a minor inconvenience but one that will empower our team to:

  • Craft the content of most use and interest to you and your colleagues
  • Put together email newsletters that contain on-point industry news
  • Provide information about online events and resources of top value to you
  • Keep you up to date on developments in the segments you are most interested in.

Without registration, visitors will still be able to read up to two articles in a 30-day period. However, to read more OSP content than that, we ask you to take a moment to register.

If you are a current newsletter subscriber (thank you for your patronage), you will still need to register to read more than two articles every 30 days. Don’t worry; you will keep receiving the email updates that you already opted-in for (visit our email preference hub to manage them).

What’s more, Outsourcing-Pharma only requires registration for unlimited access to our news content. Readers like you can visit our other pages (resources, promotional features listing pages, and the homepage) without registration.

Thank you for continuing to be a loyal Outsourcing-Pharma reader. It’s true that change can be difficult, but this one is easy and will enable us to serve readers like you even better in the future.

Related news

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more